Lipid droplets and ferritin heavy chain: a devilish liaison in human cancer cell radioresistance

  1. Luca Tirinato  Is a corresponding author
  2. Maria Grazia Marafioti
  3. Francesca Pagliari  Is a corresponding author
  4. Jeannette Jansen
  5. Ilenia Aversa
  6. Rachel Hanley
  7. Clelia Nisticò
  8. Daniel Garcia-Calderón
  9. Geraldine Genard
  10. Joana Filipa Guerreiro
  11. Francesco Saverio Costanzo
  12. Joao Seco  Is a corresponding author
  1. Magna Graecia University, Italy
  2. German Cancer Research Center, Germany
  3. University of Lisbon, Portugal
  4. DKFZ - German Cancer Research Center, Germany

Abstract

Although much progress has been made in cancer treatment, the molecular mechanisms underlying cancer radioresistance (RR) as well as the biological signatures of radioresistant cancer cells still need to be clarified. In this regard, we discovered that breast, bladder, lung, neuroglioma and prostate 6 Gy X-ray resistant cancer cells were characterized by an increase of Lipid Droplet (LD) number and that the cells containing highest LDs showed the highest clonogenic potential after irradiation. Moreover, we observed that LD content was tightly connected with the iron metabolism and in particular with the presence of the ferritin heavy chain (FTH1). In fact, breast and lung cancer cells silenced for the FTH1 gene showed a reduction in the LD numbers and, by consequence, became radiosensitive. FTH1 overexpression as well as iron-chelating treatment by Deferoxamine were able to restore the LD amount and RR. Overall, these results provide evidence of a novel mechanism behind RR in which LDs and FTH1 are tightly connected to each other, a synergistic effect which might be worth deeply investigating in order to make cancer cells more radiosensitive and improve the efficacy of radiation treatments.

Data availability

All data generated or analyzed during this study are included in the manuscript and supporting files. All Source data files have been provided.

Article and author information

Author details

  1. Luca Tirinato

    Magna Graecia University, Catanzaro, Italy
    For correspondence
    tirinato@unicz.it
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9826-2129
  2. Maria Grazia Marafioti

    German Cancer Research Center, Heidelberg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  3. Francesca Pagliari

    German Cancer Research Center, Heidelberg, Germany
    For correspondence
    f.pagliari@dkfz.de
    Competing interests
    The authors declare that no competing interests exist.
  4. Jeannette Jansen

    German Cancer Research Center, Heidelberg, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8625-3978
  5. Ilenia Aversa

    German Cancer Research Center, Heidelberg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  6. Rachel Hanley

    German Cancer Research Center, Heidelberg, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2627-1146
  7. Clelia Nisticò

    Magna Graecia University, Catanzaro, Italy
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0787-9527
  8. Daniel Garcia-Calderón

    German Cancer Research Center, Heidelberg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  9. Geraldine Genard

    German Cancer Research Center, Heidelberg, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9495-0335
  10. Joana Filipa Guerreiro

    University of Lisbon, Lisboa, Portugal
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1960-603X
  11. Francesco Saverio Costanzo

    Magna Graecia University, Catanzaro, Italy
    Competing interests
    The authors declare that no competing interests exist.
  12. Joao Seco

    DKFZ - German Cancer Research Center, Heidelberg, Germany
    For correspondence
    j.seco@dkfz.de
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9458-2202

Funding

AIRC (800924)

  • Luca Tirinato

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2021, Tirinato et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,900
    views
  • 367
    downloads
  • 36
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Luca Tirinato
  2. Maria Grazia Marafioti
  3. Francesca Pagliari
  4. Jeannette Jansen
  5. Ilenia Aversa
  6. Rachel Hanley
  7. Clelia Nisticò
  8. Daniel Garcia-Calderón
  9. Geraldine Genard
  10. Joana Filipa Guerreiro
  11. Francesco Saverio Costanzo
  12. Joao Seco
(2021)
Lipid droplets and ferritin heavy chain: a devilish liaison in human cancer cell radioresistance
eLife 10:e72943.
https://doi.org/10.7554/eLife.72943

Share this article

https://doi.org/10.7554/eLife.72943

Further reading

    1. Cancer Biology
    2. Genetics and Genomics
    Hirokazu Kimura, Kamel Lahouel ... Nicholas Jason Roberts
    Research Article

    Interpretation of variants identified during genetic testing is a significant clinical challenge. In this study, we developed a high-throughput CDKN2A functional assay and characterized all possible human CDKN2A missense variants. We found that 17.7% of all missense variants were functionally deleterious. We also used our functional classifications to assess the performance of in silico models that predict the effect of variants, including recently reported models based on machine learning. Notably, we found that all in silico models performed similarly when compared to our functional classifications with accuracies of 39.5–85.4%. Furthermore, while we found that functionally deleterious variants were enriched within ankyrin repeats, we did not identify any residues where all missense variants were functionally deleterious. Our functional classifications are a resource to aid the interpretation of CDKN2A variants and have important implications for the application of variant interpretation guidelines, particularly the use of in silico models for clinical variant interpretation.

    1. Cancer Biology
    2. Developmental Biology
    Sara Jaber, Eliana Eldawra ... Franck Toledo
    Research Article

    Missense ‘hotspot’ mutations localized in six p53 codons account for 20% of TP53 mutations in human cancers. Hotspot p53 mutants have lost the tumor suppressive functions of the wildtype protein, but whether and how they may gain additional functions promoting tumorigenesis remain controversial. Here, we generated Trp53Y217C, a mouse model of the human hotspot mutant TP53Y220C. DNA damage responses were lost in Trp53Y217C/Y217C (Trp53YC/YC) cells, and Trp53YC/YC fibroblasts exhibited increased chromosome instability compared to Trp53-/- cells. Furthermore, Trp53YC/YC male mice died earlier than Trp53-/- males, with more aggressive thymic lymphomas. This correlated with an increased expression of inflammation-related genes in Trp53YC/YC thymic cells compared to Trp53-/- cells. Surprisingly, we recovered only one Trp53YC/YC female for 22 Trp53YC/YC males at weaning, a skewed distribution explained by a high frequency of Trp53YC/YC female embryos with exencephaly and the death of most Trp53YC/YC female neonates. Strikingly, however, when we treated pregnant females with the anti-inflammatory drug supformin (LCC-12), we observed a fivefold increase in the proportion of viable Trp53YC/YC weaned females in their progeny. Together, these data suggest that the p53Y217C mutation not only abrogates wildtype p53 functions but also promotes inflammation, with oncogenic effects in males and teratogenic effects in females.